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Introduction
The defining feature of a tumor has hitherto been its 
organ of origin, thus determining the treatment strategy 
that is most beneficial for patients suffering from a ma-
lignant disease. It follows from this concept that carcinomas 
of the distal bile duct (dCC) and ductal adenocarcinomas 
of the pancreas (PDAC) are defined as two independent 
tumor entities. This is in accordance with the current 
WHO classification of tumors, which distinguishes between 
tumors of the liver and intrahepatic bile ducts, tumors 
of the gallbladder and extrahepatic bile ducts, and tumors 
of the exocrine pancreas. Here, dCC is defined by the 
location of the main tumor mass only, not by the 
 microscopic aspect [1]. Given the spatial proximity of 
the duodenal curve, the pancreatic head, and the extra-
hepatic bile duct in the epigastric region, discriminating 
these single- organ structures with accuracy reveals con-
stitutional limitations. The intertwined anatomy of the 
proximal pancreatic duct and the distal bile duct (pervading 
the pancreatic head) gives ample reason to believe that 
both structures share more common features than previ-
ously believed. Moreover, both organs developed along 
similar embryological paths, and thus share numerous 
phenotypic characteristics. This hypothesis is corroborated 
by the fact that tumors of the distal bile duct and the 
pancreatic head also share the functional characteristics: 
a similar growth pattern, poor response to conventional 
chemotherapy, and a fairly unfavorable prognosis. We 
postulate that dCC and PDAC are a common tumor entity 
or should at least be subsumed under a common super-
family. Ampullary cancer, more particularly the pancrea-
tobiliary subtype, should be considered as a part of this 
superfamily of tumors of the pancreatobiliary junction. 
The objective of this review is to define the common 
features as well as certain differences between these tumor 
entities, with regard to the embryonical development of 
the organ of origin, their diagnostic discrimination, his-
topathological and molecular similarities, and surgical and 
oncological treatment.
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Abstract
The set definition of distal cholangiocarcinomas and adenocarcinomas of the pan-
creatic head is challenged by their close anatomical relation, similar growth pattern, 
and corresponding therapeutic outcome. They show a mutual development during 
embryologic organ formation and share phenotypic characteristics. This review will 
highlight the similarities with regard to the common origin of their primary organs, 
histopathological similarities, and modern clinical management. Thus, we propose 
to subsume those entities under a common superfamily.
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The Embryologists View
Although biliary epithelial cells coat both the intrahepatic 
as well as the extrahepatic bile ducts, their developmental 
origins are distinct depending on their location in the 
biliary tree.
During the development of the gastrointestinal system, 
the endoderm forms the primitive gut. In the junction 
between the foregut and midgut that evolves into the 
duodenum, two outpunchings of the foregut form the so- 
called ventral and the dorsal bud, which serve as the basis 
for the pancreas and parts of the bile duct system. The 
larger bud, located on the dorsal aspect of the primitive 
gut forms the cranial part of the pancreatic head, the 
body, and the tail of the pancreas including their corre-
sponding ductal tree. The smaller ventral bud forms the 
caudal section of the pancreatic head, the uncinate process 
and the proximal part of the main pancreatic duct (Duct 
of Wirsung). The distal bile duct also has its origin in 
the ventral bud and temporarily forms a common channel 
with the proximal part of the main pancreatic duct. As 
the embryo develops, the ventral bud, containing the primi-
tive proximal pancreatic duct and distal bile duct, rotates 
dorsally and fuses with the dorsal bud. The proximal part 
of the pancreatic duct system in the dorsal bud obliterates 
completely. In some cases this obliteration is incomplete 
and the mostly nonfunctional, accessory pancreatic duct 
(duct of Santorini) persists. The remaining ductules of 
the dorsal bud fuse with the ductal system of the ventral 
duct. Meanwhile, the distal bile duct and the pancreatic 
duct separate and remain connected solely at the duodenal 
conjunction, the so- called ampulla of Vater [2, 3]. If the 
rotation, and particularly the fusion of the ventral and 
dorsal duct are impaired, two separate pancreatic ducts 
remain and a so- called pancreas divisum is formed (Fig. 1).
The hepatic diverticulum, which develops from the 
ventral foregut and remains attached to the abovemen-
tioned ventral bud, forms the basis for liver development. 
Mesenchymal cells surrounding the septum transversum 
induce progenitor cell differentiation into hepatoblasts, 
and stimulate the creation of the livers glandular structure. 
In the course of this development, biliary epithelial cells 
arise from hepatoblasts in the periportal layer. During 
the following phase of ductal plate remodeling, focal dila-
tions of the aforementioned biliary epithelial cell precursors 
form bile ducts. Multiple defects in ductal plate remodeling 
lead to the formation of cysts rather than bile ducts, 
resulting in the so- called Alagille syndrome [4].
In conclusion, the proximal pancreatic and the distal bile 
duct arise from common endodermal structures, thus reveal 
mutual characteristics in organ development and formation. 
In contrast, the pancreatic duct leading from central and 
caudal part of the pancreas originates from a separate 
endodermal portion. The intrahepatic bile duct system in 
contrast to the extrahepatic bile duct, takes its origin from 
periportal hepatoblasts in the hepatic diverticulum.
PDAC and dCC: Analogies in Tumor 
Genesis
Intrahepatic cholangiocarcinomas (IH- CC) are especially 
known for their histological diversity. Until recently, it 
was thought that this neoplasm is mostly likely derived 
from biliary epithelial cells, whereas it is now thought 
that this cancer can alternatively take its origin from 
 hepatic progenitor cells. In opposition, extrahepatic chol-
angiocarcinoma (EH- CC) arises from the biliary epithelium 
and the peribiliary glands [5]. It is therefore of particular 
interest that a subset of pancreatic exocrine acini are 
physiologically interspersed within these same peribiliary 
glands [6]. Three cell types have been identified in these 
acini: acinar cells with eosinophilic zymogen- like granules, 
clear cells resembling centrioacinar cells and ductular ele-
ments. Additionally, peribiliary glands have been found 
to contain trypsin and amylase enzymes [7]. A recent 
comparative study in transgenic mice as well as human 
tissue, focusing on precursors of PDAC underlined that 
PDACs originate from the ductal system and adjacent 
structures [8]. It has been suggested that PDAC develops 
in the centroacinar–acinar compartment by acinar- ductal 
metaplasia. Pancreatic intraepithelial neoplasia (PanIN) 
lesions have been shown to be the precursor lesions of 
PDAC [9]. In transgenic mouse models, mucin- producing 
Figure 1. Pancreas divisum with main pancreatic duct and duct of 
Santorini in endoscopic retrograde cholangiopancreatography.
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ductular structures are frequently observed within the 
acinar parenchyma. These structures could represent an 
intermediate stage preceding the development of mouse 
PanIN. Another study analyzed the incidence and distri-
bution of these ductular structures with and without 
mucinous metaplasia (mucinous tubular complexes/MCTs 
or tubular complexes/TCs). It could be demonstrated that 
the MCTs and TCs are common lesions in human pan-
creas. Furthermore, the expression of acinar markers, for 
example, trypsin was upheld in PanIN lesions [10]. In 
conclusion, these results indicate that the origin of PDAC 
lies in the periphery of the ductal system. Therein lies a 
strong parallelism to the origin of EH- CC, which also 
arises from the peribiliary and therefore periductal glands.
Intraepithelial neoplasia have been identified as prema-
lignant lesions in several organs such as the pancreas 
(PanIN) or the prostate (PIN). Biliary intraepithelial neo-
plasia (BilIN) is assumed to be premalignant lesions of 
the bile duct system [11]. BilINs are located both in the 
extrahepatic bile ducts and in the major intrahepatic bile 
ducts. By analogy to ductal carcinomas of the pancreas 
(PanIN 1 to PanIN 3), BilINs are classified into three 
grades [12]. BilIN- 1 describes low- grade dysplasia with 
mild cellular/nuclear atypia, BilIN- 2 is defined as inter-
mediate grade whereas BilIN- 3 stands for high- grade dys-
plasia and contains significant cellular and nuclear atypia. 
On account of the fact that BilIN- 3 corresponds to a 
carcinoma in situ, it considered as an overt cancer of 
the bile ducts. A comparison between BilIN and PanIN 
reveals impressive similarities. In conclusion, BilIN should 
be seen as a biliary counterpart of PanIN (Fig. 2).
Recently, intraductal papillary mucinous neoplasms 
(IPMN) of the pancreas were identified as precursor  lesions 
with high malignant potential [13]. Especially main duct 
IPMNs are associated with a high risk for transformation 
into intraductal papillary mucinous carcinomas (IPMC) 
[14]. It is current consensus that two different precursor 
lesions in the pancreas have to be distinguished, namely 
PanINs and IPMNs. If one assumes that BilINs are the 
biliary counterpart of PanINs, is there also a biliary coun-
terpart for IPMN? Biliary papillomas/papillomatosis may 
present suitable candidates, due to their role as prema-
lignant lesions for invasive biliary carcinomas. Furthermore, 
biliary papillomas/papillomatosis and IPMN possess similar 
clinicopathological features [15]. By virtue of this analogy, 
an alternative name was proposed for biliary papillomas/
papillomatosis, namely the intraductal papillary neoplasm 
of the biliary tract (IPNB).
IPNBs are located in the extrahepatic bile duct (primarily 
hilar and distal), as well as in larger intrahepatic bile ducts. 
Furthermore, invasive IPNB lesions show elements from both 
tubular adenocarcinoma and mucinous carcinoma, which is 
also a well- studied invasion pattern in IPMNs. In conclusion, 
biliary preneoplastic lesions and pancreatic precurser lesions 
share common characteristics. Both, PanINs and IPMNS 
have a corresponding counterpart in the biliary tract: BilINs 
and IPNBs (Fig. 2). Premalignant lesions congruent with 
those concepts have not yet been described for ampullary 
cancer. The Ampulla Vateri is the epithelial junction of the 
main pancreatic duct and the distal bile duct. Ampullary 
cancer may arise either from the intestinal epithelium or 
the pancreatobiliary ducts [16]. The pancreatobiliary subtype 
Figure 2. Biliary preneoplastic lesions and pancreatic precurser lesions share common characteristics. Both, PanINs (Intraepithelial neoplasia of the 
pancreas) and IPMNs (intraductal papillary mucinous neoplasms) have a corresponding counterpart in the biliary tract: BilINs (Biliary intraepithelial 
neoplasia) and IPNBs (intraductal papillary neoplasm of the biliary tract).
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shows a positive correlation with a higher rate of tissue 
invasion, lymph node metastasis, and a worse outcome, than 
the intestinal type [17]. Thus, it has been hypothesized that 
the pancreatobiliary subtype should be seen as a very distal 
PDAC or dCC. In accordance with the aforementioned con-
cept, PDAC and dCC and ampullary adenocarcinoma should 
be considered as a common tumor entity [16]. Never the 
less, the focus of this review remains the comparison of 
PDAC and dCC subentities.
Molecular Pattern: Differences and 
Analogies Between PDAC and EH- CC
The two most commonly mutated genes in PDAC are 
p53 and KRAS. Activating KRAS mutations can be found 
in up to 95% of PDACs [18]. It is of particular interest 
that KRAS mutations are present in 90% of early stage 
PDACs, as well as in premalignant lesions such as PanINs 
[19, 20]. Through the analysis of KRAS mutations in biliary 
tract neoplasms and their corresponding premalignant 
 lesions, Hsu et al. proved a similar process of carcinogenesis 
in the progression of BilINs to CCs [21]. Moreover, a 
recent study reports that KRAS mutations are present in 
61.1% of the ampullary cancers, but only in 15.2% of 
bile duct and 2.7% of gallbladder cancers [22].
One of the key players of physiological apoptotic re-
sponse, tumor suppressor gene p53, is frequently subject 
to mutations in CC as well as PDAC. Khan et al. reported 
mutation rates of 20% to 61% for dCC [23], and another 
study determined that a low (0–30%) p53 expression 
showed a favorable prognostic factor in patients with 
resected dCC [24]. In PDAC, p53 mutations can be found 
in up to 70% of primary, and in more than 50% of 
metastatic pancreatic cancers [25–27].
Unlike KRAS, p53 mutations seem to be a late event in 
the development of PanINs to PDAC [20, 28]. Nevertheless, 
p53 has already been the subject of therapeutic approaches 
in PDAC. Transfer of the p53 gene via vectors has lead to 
an inhibition of tumor cells in vitro as well as in vivo [29, 
30]. It is of further note that mutant p53 stimulates chem-
oresistance against gemcitabine, and the reintroduction 
 (reactivation) of p53 increases the cytotoxicity of gemcitabine 
[31, 32]. Despite the aforementioned results, no attempt to 
evaluate p53 as a therapeutic target has been made in CC.
In recent years, miRNAs have emerged as diagnostic, as 
well as therapeutic targets in multiple cancers. miRNAs are 
small, noncoding RNAs that influence multiple physiological 
and pathological processes on the post- transcriptional level. 
Furthermore, they have been identified as crucial players 
in carcinogenesis due to their role as both oncogenes and 
tumor suppressors. miR- 21 as well as let- 7a undergo an 
upregulation in PDAC and CC, [33] and may additionally 
modulate gemcitabine- induced apoptosis, thus lending these 
molecules a potential therapeutic relevance [34]. In a similar 
study, the targeted inhibition of miR- 21 via lentoviruses 
leads to a significant regression of PDAC tumor growth in 
vivo [35].
Despite these promising results, current literature does 
not enable a direct comparison of miRNA expression levels 
in PDAC and CCs. Furthermore, many projects do not 
distinguish between IH- CCs and EH- CCs, rendering a sci-
entifically based conclusion on the similarities and difference 
between PDAC and dCCs impossible (Table 1) [36].
The Pathologists View: Are There 
Phenotypical Similarities Between 
PDAC and dCC?
The diagnosis of PDAC has hitherto been based on the 
identification of tumor markers such as CEA, CK19- 9, 
CK7, and CK20, in conjunction with its histological and 
clinical characteristics.
Cytokeratin (CK) 7 is a pancreatobiliary marker 
 expressed in IH- CC, EH- CC, and pancreatic neoplasms 
[37–42]. Similarly, CEA and CK19- 9 are also expressed 
by all three tumor entities [16]. Cytokeratin 20 shows a 
more nuanced expression, in that it revealed high expres-
sion in EH- CCs and variable negative expression in IH- 
CCs [39]. In PDAC, CK20 expression was highest in 
tumors with a high number of reactive cells [40], despite 
an overall more common CK7+/CK20- phenotype [40–42]. 
Nevertheless, other studies suggest higher expression rates 
(65%) for CK20 in pancreatic cancer, and a plausible 
negative prognostic significance of the marker [43]. 
Interestingly, the pancreatobiliary subtype of ampullary 
cancer lacks CK20 in majority of cases whereas the in-
testinal subtype shows a high CK20 expression [16, 44].
In conclusion, common tumor markers such as CK7, 
CEA, and CK19- 9 are unable to differentiate IH- , EH- 
CCs, and PDAC. Moreover, although CK20 shows a subtler 
expression prolife (low in IH- CC, high in EH- CC, and 
variable expression in PDAC), it demonstrates a high 
biological and methodical variability, rendering it an 
 unreliable marker for pancreatobiliary cancers.
The inadequacies of current tumor marker panels have 
led to the exploration of alternative indicator molecules, 
among which proteins from the mucin and cadherin fam-
ily have taken on a distinctive role. Such research could 
be valuable for identifying potential tumor subentities and 
further describing their clinical behavior, that is, drug 
response, overall survival, and rate of metastasis/invasion. 
Specific targeting of strongly expressed antigens could also 
lead to personalized therapeutic interventions.
Mucins (MUC) are high- molecular, highly glycosylated 
proteins that form biological gels as a means of protecting 
epithelia from their external conditions. Furthermore, 
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mucins play an important role in cell- to- cell signaling, 
and inducing immune reactions [45]. A set of twenty 
different mucins has been identified in human epithelia, 
each glycosylated differently in order to carry out a specific 
function [46]. Despite this biological variety, this com-
parative analysis will focus on solely MUC1 and MUC4 
as potential tumor markers.
MUC1 has been identified in both pancreatic and so- 
called “mucin- producing” cholangiocarcinomas derived 
from the large bile ducts of the liver [47–50]. Tamada 
et al. revealed that while MUC1 is not expressed in normal 
epithelia of the bile duct, it can be found in 87% of 
EH- CC tumors analyzed (n = 70) [51]. More importantly, 
MUC1 showed an analogous expression pattern in biliary 
intraepithelial and pancreatic intraepithelial neoplasms 
[52]. Furthermore, MUC1 may promote cell adhesion in 
foreign tissues, and thus allows for PDAC invasion [53]. 
In comparison to the above mentioned MUC1- expressing 
tumors, mixed- type CCs, and cholangiocarcinomas (deriv-
ing from hepatic progenitor cells rather than cholangio-
cytes) only produce negligible amounts of MUC1 [47].
Interestingly Remmers et al. showed that MUC1’s ex-
pression and glycosylation pattern transformed from nor-
mal tissue to premalignant and cancerous tissues of the 
pancreas [46]. This study detailed that unglycolyzed MUC1 
was highest in metastatic tissue, whereas “T- MUC1” (a 
specifically glycolyzed form of the protein) expression was 
lowest in normal tissue. Hence, MUC1 could potentially 
be used to map the progression of normal to malignant 
tissue in both pancreatic and extrahepatic biliary 
cancer.
Although MUC1 functions as a membrane receptor, 
MUC4 may bind to the ErbB2 receptor, possibly increas-
ing p27 Expression [54]. Several studies have shown that 
while MUC4 is not present in normal liver or pancreatic 
tissue, it is present in PDAC, EH- CC, and IH- CC derived 
from the larger bile ducts [46, 51, 55–57]. More impor-
tantly, it has been identified as a negative prognostic factor 
for survival in all three tumor types correlating with higher 
metastatic and lymphatic invasion [55–57]. In IPMN’s of 
the pancreas, MUC4 may enable a differentiation between 
malignancies of the intestinal type and the gastric type 
[56]. Unfortunately, data on MUC4 expression in mixed- 
type CCs is scant.
Proteins from the cadherin family have also recently 
come into the spotlight as potential indicator substances 
for gastrointestinal neoplasms. Cadherins play an important 
role in cell adhesion and cell communication, both as 
receptors and ligands within signaling pathways. 
Additionally, it has been postulated that during epithe-
lial–mesenchymal transition (EMT) a so- called “cadherin 
switch” comes into effect, in which E- Cadherin, typically 
expressed in epithelia, is replaced by N- Cadherin, found 
mostly in mesenchymal tissue [58]. E- Cadherin has proved 
Table 1. Summary of similarities and differences in IH- CC, EH- CC, dCC, and PDAC.
IH- CC EH- CC and dCC PDAC References
Developmental origin Mesenchymal cells surrounding 
the septum transversum form 
small intrahepatic bile ducts
Ventral part of forgut forms 
main extrahepatic bile ducts
Ventral part of forgut forms 
mainpancreatic duct
[2–4]
Tumor genesis Hepatocytes, hepatic 
 progenitor cells or BECs
Ductal system or periductal 
glands
Ductal system or periductal 
glands
[5–8]







Precursor lesions with 
malignant potential
No corresponding lesions in 
IH- CC
Intraductal papillary 
 mucinous neoplasms (IPMN)
Intraductal papillary neoplasm 
of the biliary tract (IPNB)
[13–15]
Molecular pattern KRAS+/− KRAS+ KRAS+ [18–27]
p53+/− p53+ p53+
Phenotype CK20− CK20+ CK20+ [39–43, 46–52, 
55–57]MUC1+/− MUC1+ MUC1+
MUC4+ (only larger bile ducts) MUC4 + MUC4+
S100P+ (only larger bile ducts) S100P + S100P+
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to be a protective factor in both CC and PDAC [59]. 
Nitta and Mitsuhashi et al. recently showed that N- Cadherin 
was a negative prognostic factor for survival in EH- CC, 
a finding confirmed by Araki et al. [60, 61]. Elevated 
expression of N- Cadherin in IH- CC was also linked to 
aggressive behavior with increased metastasis and invasion 
[62]. However, a recent study was able to show that N- 
Cadherin expression was significantly lower in metastatic 
liver PDAC than in CCs, possibly enabling a differentia-
tion of these tumor subtypes in conjunction with other 
markers [63]. Unfortunately, this study did not discriminate 
between subentities of cholangiocarcinoma.
Finally, S100p encodes a family of proteins responsible 
for regulating differentiation and proliferation. Ali et al. have 
identified this protein as a highly specific and sensitive marker 
for pancreatobiliary tumors, achieving 100% specificity and 
83% sensitivity on its own [64]. By means of a histological 
panel including S100p, MUC1, KOC, and mesothelin, the 
diagnosis of pancreatobiliary tumors was achieved to nearly 
100% specificity and sensitivity, in cytological specimens 
sampled through endoscopic retrograde cholangiopancrea-
tography (ERCP). Other studies confirm high S100p expres-
sion in PDAC and EH- CC, in contrast to infrequent expression 
in normal pancreatobiliary tissue [65]. A recent study showed 
that S100P staining identified IH- CCs with bile duct mor-
phology (a.k.a derived from the larger ducts of the biliary 
tree) to have a similar expression profile (CEA+, CK19- 9+, 
MUC2+, and more likely N- Cadherin negative) to EH- CC 
and PDAC [66]. S100p negative tumors showed less of a 
bile duct morphology and were more likely to be N- Cadherin 
negative, Liau et al. confirmed a higher expression of S100p 
in IH- CC of bile duct morphology.
Although EH- CC and PDAC show many similarities 
concerning the expression of MUC1 and S100P, IH- CC 
derived from the small bile ducts seem to have a different 
phenotype. MUC4, N- Cadherin may also prove to be 
useful markers, given further study. In conclusion, stand-
ardized immunohistochemical panels including atypical 
marker proteins should be further evaluated in order to 
improve the accuracy of IH- CC and EH- CC diagnosis.
Assigning a Diagnosis: Imaging 
Strategies for PDACs and dCCs in 
Light of Common Features and 
Anatomical Difficulties
Diagnostic methods for discriminating cancers of the pan-
creatic head and the distal bile duct often overlap. In this 
chapter, we aim to highlight common features and chal-
lenges in the discernment of the abovementioned entities.
The early detection of the tumor is crucial for the prog-
nosis of PDAC and dCC patients. Both neoplasms arise 
from ductal epithelia, and therefore tend to grow in lon-
gitudinal alignment with the ductal system during the early 
stages of tumor formation. It is due to this mechanism 
that mass formation occurs mostly in the later stages of 
the tumor development, impeding an early, and thus 
 potentially curative, image- based diagnosis. In contrast, 
IH- CCs show a distinct growth pattern (including con-
centric growth and mass formation), thus facilitating tumor 
detection in an abdominal ultrasound (US), computed 
tomography (CT), and/or magnetic resonance imaging 
(MRI) (Fig. 3). Therefore, the longitudinal rather than 
concentric growth pattern of PDAC and dCC severely 
Figure 3. Tumors are classified according to their location (from top to bottom): intrahepatic cholangiocarcinoma (IH- CC), hilar cholangiocarcinoma, 
distal cholangiocarcinoma (dCC), and adenocarcinoma of the pancreas (PDAC).
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restricts image- based screening, due to their limited sen-
sitivity. Through a comparison of CT, MRI, magnetic 
resonance cholangiopancreatography (MRCP), and the 
endoscopic ultrasound (EUS), the CASPS3 study showed 
that the best visualization of small pancreatic lesions could 
be achieved by EUS and MRCP [67]. This result may be 
explained by the occurrence of neoplastic obstruction of 
the ductal system, which can occur in early stages of PDAC 
and dCC progression when the tumor itself is not yet 
detectable via radiological assessment. An additional benefit 
of the EUS is the possibility to take samples via fine needle 
aspiration or brush cytology. A sufficiently large tumor 
sample can discriminate between benign and malignant 
lesions in selected cases. Studies on intraductal endoscopic 
ultrasound (IEUS) took the EUS approach to dCC and 
PDAC identification a step further, and demonstrated that 
the diagnosis of bile duct strictures and lesions of the 
pancreatic head can be improved by the assessment of 
the ductal wall and its surrounding structures [68–70]. In 
comparison to IH- CCs and lesions of the caudal pancreas, 
PDACs and dCCs can be easily assessed via ERCP, EUS, 
and IEUS. Furthermore, the early diagnosis of the latter 
tumor entities is mostly based on the visualization of the 
concomitant cholestasis. A large portion of PDACs, dCCs 
as well as ampullary cancers clinical symptoms, result from 
cholestasis due to neoplastic obstruction. Therefore, tumors 
with a high cholestatic effect are often diagnosed at an 
earlier stage due to their prompt onset of symptoms. The 
same explanation may clarify the slightly higher survival 
of dCC as compared to PDAC: tumors located in the 
corpus or cauda of the pancreas will not cause cholestasis 
in the early stages of the condition. Another reason for 
this finding might be the fact that some studies include 
ampullary cancer (a neoplasm with an overall more  favorable 
prognosis) into prognosis estimation of dCC [71].
Due to the contiguity of PDACs and dCCs, the dis-
crimination of these neoplasms can be particularly chal-
lenging. A clear anatomical attribution can be especially 
difficult in later tumor stages, when malignant growth 
involves neighboring structures. Applying the hypothesis 
of a common superfamily for those tumor entities, a dis-
tinction according to the organ of origin would be obsolete. 
The common tumor entity approach becomes a depiction 
of clinical reality in that the only possibility for curative 
treatment, that is a radical surgical resection, is congruent 
concerning the surgical technique for PDAC and dCC.
The Surgeons Point of View: Surgical 
Treatment Options in PDAC and CCs
Radical surgical resection with a microscopic tumor- free 
resection margin (R0), is the only curative option for 
PDAC and CC [72]. The guiding principle behind radical 
resection applies to the whole range of tumors of the 
pancreatobiliary system, regardless of their location. Thus, 
the procedure of choice for hilar cholangiocarcinoma 
(Klatskin tumor) is an extended hemihepatectomy, with 
en bloc extrahepatic bile duct resection. This procedure 
has a clear advantage regarding the local recurrence rate 
and overall survival time, as compared to alternative strate-
gies. Neuhaus et al. described a 1- , 3- , and 5- year survival 
rate after hilar en bloc resection, which included the re-
moval of the portal vein bifurcation, of 87%, 70%, and 
58%, respectively. Survival rates after conventional major 
hepatectomy were significantly lower with 1- , 3- , and 5- 
year survival rates of 79%, 40%, and 29%, respectively 
[73]. Due to the spatial proximity of the duodenum, the 
pancreatic head, the extrahepatic bile duct, and their 
overlapping blood supply, curative resections of both PDAC 
and dCC require a pancreatoduodenectomy, preferably 
under preservation of the pylorus (PPPD). In selected 
cases of ampullary cancer, a local resection via transduo-
denal ampullectomy or an endoscopic resection can be 
considered [74]. As a result of the longitudinal spread 
of the tumor in the bile duct wall, an additional hemi-
hepatectomy has to be considered in selected cases in 
order to achieve an R0 resection [75]. From a surgeon’s 
point of view, a suspected malignant lesion located in 
the pancreatic head – regardless of whether it arises from 
the pancreatic or the bile duct – needs to be removed 
in toto using an identical surgical technique.
The Oncologists Perspective: How Do 
Pancreatobiliary Tumors Respond to 
Conventional Adjuvant 
Chemotherapy?
There are various therapeutic options for pancreatobiliary 
cancers, namely PDAC, IH- CC, and EH- ICC [76, 77]. 
Nevertheless, most patients diagnosed with these types of 
cancer have a low survival rate and die within the first 
one to three years of diagnosis with or without chemo-
therapeutic treatment [78–80].
Common therapeutic agents for pancreatobiliary cancers 
include antimetabolites such as 5- fluorouracil (5- FU) [80, 
81] and capecitabine [82–84], nucleoside analogs such as 
gemcitabine [85–90], platinum analogs such as oxaliplatin, 
[82–84] and cisplatin [91, 92]. In recent studies, chemicals 
known as taxenes in form of nab- paclitaxel, a 130- nm 
albumin- bound formulation of paclitaxel particles, have 
been evaluated to this end [93].
While 5- FU is not the first preference for adjuvant 
chemotherapy of PDAC and is only reported to have 
minimal effects on overall survival [81], it has a much 
bigger impact on IH- CC and EH- CC. A retrospective 
study by Yoshitda et al. including 26 patients with distal 
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bile duct cancer after pancreaticoduodenectomy, reports 
a 5- year- survival rate of 56% with adjuvant chemotherapy 
compared to 27% for untreated patients [80]. Similarly, 
another study carried out with a collective of 35 patients 
with intraductal papillary peripheral cholangiocarcinoma, 
accounts for a 5- year- survival rate of 33.3% for treated 
and 10.8% for untreated patients [79].
Gemcitabine, on the other hand, has been used very 
successfully in adjuvant chemotherapy to increase the 
overall survival rates of patients suffering from PDAC, 
exemplary shown within the scope of the CONKO Study 
by Sinn et al. [94, 95].
A multicentered, randomized, phase III, clinical trial com-
pared the effects of gemcitabine with 5- FU for pancreatic 
carcinoma in first- line palliative setting. The study concluded 
that the clinical benefits (23.8% vs. 4.8%) as well as the 
12- month survival rate (18% vs. 2%) were both significantly 
greater for gemcitabine than for 5- FU, respectively [90].
A similar therapeutic effect has been reported for 
Gemcitabine in EH- CC. According to Murakami et al. 
the 5- year- survival rate of patients who received adjuvant 
chemotherapy with gemcitabine after extended surgery for 
hilar cholangiocarcinoma, was noticeably higher (57%) 
compared to those who did not receive any postoperative 
treatment (23%) [85]. For IH- CC, however, Gemcitabine 
is reported to have minimal effect [86]. Thus, the clinical 
response to gemcitabine is similar for PDAC and EH- CC, 
in contrast to IH- CC.
Several alternative treatment protocols for pancreato-
biliary cancers involve platinum- based therapeutic agents. 
The combination therapy of capecitabine and oxaliplatin 
(CapOx), for example, offers a different treatment for 
PDAC with similar outcomes to gemcitabine- related 
 regimes [84]. A prospective, multicentre, phase II trial 
by Nehls et al. analyzed the response of 47 patients with 
EH- CC with respect to CapOx treatment, and compared 
the results with 18 patients with IH- CC who received the 
same chemotherapy. The response rate of the EH- CC 
collective was reported to be 27%, while there were no 
objective responses among the IH- CC patients. 
Additionally, 49% of the EH- CC had a stable disease after 
treatment compared to 33% for the IH- CC [83].
On the other hand, reports suggest that a gemcitabine 
and cisplatin combination therapy leads to different clini-
cal responses. According to an extensive phase II study 
by Valle et al. both EH- CC and IH- CC have a better 
clinical response to the above mentioned combination 
therapy, as compared to a gemcitabine monotherapy [78]. 
In PDAC, however, this combination therapy only shows 
moderate activity, highlighted by a low response rate of 
11% [88]. Hence, while PDAC and E- CC respond to 
CapOx analogically, the response is quite different for a 
gemcitabine and cisplatin combination therapy.
Recently, the use of nab- Paclitaxel in conjunction with 
gemcitabine for treating PDAC has/come into the spot-
light. A contemporary phase III study compared a col-
lective of 430 patients with PDAC on a gemcitabine 
monotherapy with 431 patients who received a combi-
nation of gemcitabine and nab- Paclitaxel. The treatment 
resulted in a higher median overall survival for the 
combination therapy collective (8.5 vs. 6.7 months), 
despite higher rates of peripheral neuropathy and 
 myelosuppression [96]. However, there have been no 
extensive clinical trials in cholangiocarcinoma popula-
tions so far. A recent study by Kolinsky et al. examined 
the therapeutic effect of nab- Paclitaxel monotherapy for 
two patients with cholangiocarcinoma and suggests that 
nab- Paclitaxel does indeed have therapeutic activity [97]. 
Considering the similarities between PDAC and EH- CC 
relative to their therapeutic response, as outlined in 
this section, future studies examining the therapeutic 
activity of a nab- Paclitaxel and gemcitabine combination 
in EH- CC are more than justified. This is of particular 
significance as chemotherapy algorithms of dCC and 
PDAC currently diverge, particularly for advanced 
disease.
Conclusion: New Thoughts and 
Concepts on Defining 
Pancreatobiliary Cancers
Carcinomas of the pancreatic head and dCCs share a 
wide range of common features. Both tumors possess a 
common embryologic origin, a marked anatomical overlap 
of the primary organ tissue, and several phenotypic analo-
gies. All of these factors explain the difficulties in dis-
criminating both tumor entities through imaging studies, 
and the exigency for radical surgical resection. Finally, 
similarities in the therapeutic outcomes of PDAC and 
extrahepatic bile duct cancer suggest strong behavioral 
analogies. Summarily, a new and unified superfamily for 
those tumor entities of the pancreatobiliary junction should 
be considered to more accurately define these neoplasms. 
We consider the definition of such a superfamily more 
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